You are correct. Nobody is selling this stock short hoping for a decline in price to cover and make a profit at this point in the traditional sense of shorting. The actual short position is very low because the risk/reward just isn't there anymore.

We have to prove beyond a shodow of doubt leronlimab works well enough to be monetized to get out of this negative financing spiral path CYDY has chosen to follow.